Buy PRCT on the Dip: A Patient Long on Robotic Urology Growth

Hook & thesis

PROCEPT BioRobotics (PRCT) is an actionable buy after a messy earnings reaction and a string of negative headlines. The company runs the AquaBeam Robotic System, the only commercially available robotic waterjet therapy for benign prostatic hyperplasia (BPH). Shares trade at $26.49 with a $1.49 billion market cap and an enterprise value of roughly $1.25 billion, pricing in significant execution risk but leaving room for upside if growth normalizes.

My thesis: the market has overreacted to a near-term guidance reset and investor litigation noise. PROCEPT still demonstrates meaningful commercial traction (Q2 2025 revenue of $79.2 million, +48% year-over-year), a conservative balance sheet (cash-like metrics and low leverage), and structural tailwinds from reimbursement parity with TURP. That combination supports a tactical long with defined risk controls.

What the company does and why it matters

PROCEPT manufactures and sells the AquaBeam Robotic System and single-use disposable handpieces to perform Aquablation therapy - a heat-free, image-guided waterjet ablation that removes prostate tissue for symptomatic BPH. This is a procedure-driven business: revenue comes from systems, disposables, and procedure adoption. The product is differentiated because it blends imaging, planning software, and automated robotics to shorten procedure times and, according to published data, preserve sexual function better than some alternatives.

Why the market should care

BPH is a large, underpenetrated market. The company reported a standout quarter in Q2 2025 (reported 08/07/2025) with revenue of $79.2 million, up 48.3% year-over-year, demonstrating tangible demand uplift for systems and consumables. Institutional adoption requires time, but the revenue cadence shows a scalable commercial channel. Importantly, Aquablation received assignment to a Category I CPT code for Medicare reimbursement with parity to TURP, effective 01/01/2026. Reimbursement clarity materially lowers the adoption hurdle for hospitals concerned about downstream procedure economics.

Key numbers to anchor the idea

Valuation framing

At a market cap near $1.49 billion and EV/sales of ~4.06x, PROCEPT trades like a high-growth medtech with execution risk priced in. The P/S multiple reflects a mix of prior rapid top-line growth and current negative profitability (EPS -$1.69 and negative FCF of $58.34 million). Compare this to the trading range: the stock peaked at $66.85 in mid-2025 when optimism about adoption ran highest, and it bottomed near $19.35 earlier in 2026 after the guidance reset.

My read: the multiple is acceptable if revenue growth re-accelerates into the $400M+ revenue corridor implied by prior guidance, and if gross-profit recovery on consumable sales continues. The balance sheet helps — leverage is low (debt/equity ~0.14) and liquidity ratios imply runway to support commercialization while margins improve. In short, the market is pricing significant execution failure; a modest re-acceleration in adoption should compress multiples and lift the stock materially from here.

Catalysts to drive the trade

• Operational stabilization after the commercial realignment that drove the guidance cut on 02/25/2026 - any signs of normalized ordering cadence or the reintroduction of bulk-purchase economics would be positive.
• Continued procedure adoption and consumable attach-rate improvement; recurring revenue from single-use handpieces scales faster than systems sale alone.
• Positive quarterly results that beat the revised guidance and show improving adjusted EBITDA trajectory.
• Fewer legal overhangs — slowing or resolution of the securities investigations would remove a headline risk premium.
• Hospital-level adoption stories and real-world outcomes showing shorter OR times or lower complication rates, supporting faster purchasing cycles.

Trade plan (actionable)

Trade direction: Long

Entry price: $26.49 (current print)

Stop loss: $19.00

Target price: $40.00

Horizon: long term (180 trading days) - I expect this trade to take multiple quarters to play out because hospital purchasing cycles and adoption curves are slow, and the company must demonstrate sequential quarter improvement after the 02/25/2026 guidance reset.

Size the position so the distance from entry to stop represents an acceptable dollar loss (e.g., a 30% haircut from entry to stop). This trade is event-driven and execution-sensitive: keep position sizing disciplined and consider scaling in on weakness or on positive quarter-to-quarter indicators.

Short-interest and technical backdrop

Short interest has been elevated historically (peaking above ~7.6M) but fell to ~6.5M as of 03/13/2026, with days-to-cover down to ~2.67 on current volume — implying shorts can be closed quickly if buying pressure hits. Recent short-volume prints show heavy activity in late March, which can amplify volatility on up days and down days alike. Technically, the 10- and 20-day SMAs are near $26 while the 50-day SMA sits near $27.5, so the stock is trading around near-term moving averages with neutral RSI (~49.7) and a slightly bullish MACD histogram.

Risks and counterarguments

• Execution risk persists. The company cut revenue guidance on 02/25/2026 and disclosed larger-than-expected adjusted EBITDA losses, which directly drove a ~15% one-day decline on 02/26/2026. If operational issues are deeper or take longer to fix, the valuation multiple could compress further.
• Litigation and headline risk. Multiple securities-fraud investigations were announced in March 2026. Even if unfounded, legal overhangs prolong investor wariness and can keep the stock depressed until clarity emerges.
• Capital intensity / negative cash flow. Free cash flow is negative (~$58.34M), and while net leverage is low, continued cash burn could force financing at unfavorable terms or dilute equity if growth stalls.
• Adoption hurdles. Hospital purchasing cycles, surgeon training, and competition from established procedures (TURP, laser enucleation) mean adoption can be slow; slower-than-expected consumable attach rates would hurt revenue leverage.
• Macroeconomic / reimbursement risk. Although Aquablation has a Category I CPT code effective 01/01/2026, changes in hospital reimbursement behavior or pressure on procedure volumes could reduce near-term uptake.

Counterargument: The pessimistic case is simple—if repeatable demand for single-use handpieces and new system placements does not materialize, PROCEPT is a cash-burning growth story that could need equity financing, compressing valuation toward the low end of the 52-week range. That scenario is realistic and explains why the stock sold off after guidance reduction.

What would change my mind

I will reassess the bullish stance if any of the following occur: another material downward revision to 2026 revenue guidance, persistent or growing adjusted EBITDA losses without a credible plan to return to profitability, evidence that hospitals are not converting trials to full adoption (low conversion of initial system placements to recurring consumable revenue), or a financing event that meaningfully dilutes existing shareholders. Conversely, a return to positive adjusted EBITDA guidance, evidence of robust consumable attach rates, or resolution of legal overhangs would strengthen conviction.

Conclusion

PROCEPT is a classic commercial-stage medtech: high optionality if adoption continues, but binary around execution. The post-02/25/2026 pullback and legal headlines have created a tactical buying window. With a $26.49 entry, a $19 stop to cap downside, and a $40 target over ~180 trading days, this trade balances upside from multiple compression and revenue re-acceleration against identifiable near-term risks. Size the position accordingly and treat the trade as conditional on visible commercial improvement and cleaner headlines over the next several quarters.

Avery Klein, TradeVae